Verona Pharma plc, a clinical stage biopharmaceutical company, develops and commercializes therapeutics to treat respiratory diseases. The company's product candidate is RPL554, an inhaled dual inhibitor of the enzymes phosphodiesterase 3 and 4, which has completed Phase I and IIa clinical trials that acts as a bronchodilator and an anti-inflammatory agent for the treatment of chronic obstructive pulmonary disease and cystic fibrosis. Verona Pharma plc was incorporated in 2005 and is headquartered in London, the United Kingdom.
Industry, Sector and Symbol
Stock Exchange LON
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
SymbolLON:VRP
CUSIPN/A
Phone+44-20-32834200
Debt
Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on Equity-30.13%
Return on Assets-26.97%
Miscellaneous
EmployeesN/A
Outstanding Shares105,020,000
Market Cap£160.79 million
Verona Pharma (LON:VRP) Frequently Asked Questions
What is Verona Pharma's stock symbol?
Verona Pharma trades on the London Stock Exchange (LON) under the ticker symbol "VRP."
How were Verona Pharma's earnings last quarter?
Verona Pharma Plc (LON:VRP) announced its quarterly earnings data on Tuesday, May, 8th. The company reported ($14.50) EPS for the quarter, topping the Zacks' consensus estimate of ($23.70) by $9.20. View Verona Pharma's Earnings History.
What price target have analysts set for VRP?
3 brokers have issued 1-year price targets for Verona Pharma's shares. Their predictions range from GBX 160 to GBX 348. On average, they expect Verona Pharma's share price to reach GBX 252.67 in the next twelve months. This suggests a possible upside of 122.6% from the stock's current price. View Analyst Price Targets for Verona Pharma.
What is the consensus analysts' recommendation for Verona Pharma?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Verona Pharma in the last year. There are currently 2 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Verona Pharma.
Who are some of Verona Pharma's key competitors?
Some companies that are related to Verona Pharma include Mesoblast (MEOBF), Emerald Health Therapeutics (EMH), Starpharma (SPL), MediGene (MDG1), Oxford BioMedica (OXB), BioTime (BTX), Resverlogix (RVX), 22nd Century Group (XXII), Protalix Biotherapeutics (PLX), Neptune Wellness Solutions (NEPT), Monash IVF Group (MVF), ABcann Global (ABCN), Horizon Discovery Group (HZD), IMV (IMV) and Faron Pharmaceuticals Oy (FARN).
Who are Verona Pharma's key executives?
Verona Pharma's management team includes the folowing people:
- Dr. Jan-Anders Karlsson, Chief Exec. Officer & Exec. Director (Age 63)
- Mr. Piers John Morgan MA, ACA, Chief Financial Officer (Age 52)
- Ms. Claire Louise Poll, Legal Counsel (Age 51)
- Dr. Peter Spargo Ph.D., Sr. VP of CMC (Age 56)
- Mr. Richard Hennings, Commercial Director (Age 48)
How do I buy shares of Verona Pharma?
Shares of VRP and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
What is Verona Pharma's stock price today?
One share of VRP stock can currently be purchased for approximately GBX 113.50.
How big of a company is Verona Pharma?
Verona Pharma has a market capitalization of £160.79 million.
What is Verona Pharma's official website?
How can I contact Verona Pharma?
Verona Pharma's mailing address is 3 More London Riverside, LONDON, SE1 2RE, United Kingdom. The company can be reached via phone at +44-20-32834200.
MarketBeat Community Rating for Verona Pharma (LON VRP)
MarketBeat's community ratings are surveys of what our community members think about Verona Pharma and other stocks. Vote "Outperform" if you believe VRP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VRP will underperform the S&P 500 over the long term. You may vote once every thirty days.
